Citi upgraded Fortrea Holdings to Buy from Neutral with a price target of $40, up from $34. The firm named Fortrea its top pick in contract research organizations and labs, citing evidence of healthy bookings, a compelling margin turnaround story underway, and attractive valuation relative to peers. Citi sees a margin improvement story with Fortrea’s multiple not yet reflecting the realization of cost benefits.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on FTRE:
- Fortrea Holdings upgraded to Outperform from In Line at Evercore ISI
- Acelyrin price target lowered to $12 from $15 at Jefferies
- Fortrea Holdings announces AI-driven partnership with Medidata
- Fortrea Announces AI-Driven Partnership with Medidata to Increase Diversity in Clinical Trials
- AstraZeneca announces launch of Evinova, a digital health solutions provider